The Neauvia team worked hand in hand with the FDA to minimize risk and improve outcomes for patients seeking this type of treatment.
Neauvia North America announced that the U.S. Food and Drug Administration (FDA) has given Class II clearance to Plasma IQ, an innovative, non-surgical solution that helps improve the appearance of aging skin in delicate areas of the face. According to the company, the device utilizes precise plasma technology to give the skin a refreshed and renewed appearance.
“Neauvia knows plasma. We are the first and only company to work hand in hand with the FDA to bring Plasma IQ to the aesthetic marketplace for safe and effective use as a Class II device. As the only manufacturer and seller of aesthetic handheld plasma devices in the U.S., we are able to deliver a device designed for the exacting needs of medical professionals. Neauvia is known worldwide as experts in the research and development of plasma. I could not be happier to bring yet another great Neauvia produced device to the U.S. market,” says Sean Wilson, president and chief executive officer of Neauvia North America.
Though plasma energy has been used for many years across different industries, its application in aesthetic medicine is still relatively new. Neauvia wanted to find a way to introduce the benefits of this technology in the United States while upholding the stringent quality and patient safety standards the brand is known for globally. The Neauvia team worked hand in hand with the FDA towards the Class II designation with the aim of minimizing risk and improving outcomes for the patients seeking this kind of treatment. The Class II designation ensures that Plasma IQ can only be used by medically licensed and certified practitioners who have been trained by Neauvia.
Plasma IQ is supported by a comprehensive suite of training materials, and the company’s clinical education is handled in-house, ensuring practitioners are well-prepared to provide safe treatments with impressive results. Plasma IQ providers always have a direct line to Neauvia’s in-house medically trained experts as they learn about and begin to leverage the revolutionary energy-based technologies that the company is bringing to market.
Plasma IQ ionizes the gas particles in the air, creating an arc between the device tip and the skin resulting in micro-injuries that trigger the body’s natural healing response. Precise technology and careful technique limit damage to the surrounding area, helping to reduce downtime, improve healing, and minimize the risk and severity of side effects.
The device is the second energy-based rejuvenation device in Neauvia North America’s product portfolio, which emphasizes a holistic approach to beauty and aging by working synergistically and safely with the body’s natural processes. The first device, Zaffiro, combines hydro-exfoliation and thermo-lifting to treat skin laxity and dullness in a wide range of treatment areas across the face and body.
Globally, Neauvia offers an extensive portfolio of products including hyaluronic acid dermal fillers, energy-based devices, and clinical-grade skincare. Neauvia remains committed to providing innovative, safe, and effective solutions for providers and their patients.
Plasma IQ is FDA cleared to be used in the removal and destruction of skin lesions and the coagulation of tissue. The most common side effects are swelling, tenderness, scabbing, and redness. Plasma IQ is Rx only and should only be used by medically licensed and certified practitioners.
[PRWeb]
